Drugs / Supemtek®
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Supemtek | — | 2026-03-30 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05409612 Comparator | Nov 2022 → Apr 2023 | morbid obesity | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Supemtek | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05409612 ↗ |
| Modality | Vaccine | “quadrivalent recombinant high-dose influenza vaccine” NCT05409612 ↗ |
| Route | Intramuscular | “Vaccine is injected intra-muscularly in the non-dominant arm at Day 0.” NCT05409612 ↗ |